myeloma

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

4 hours ago

Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting

NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma Research Foundation® (MMRF) announced that data generated from…

4 hours ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

3 months ago